Clinical Trial Update: NEO100 and High-Grade Meningioma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating NEO100 for residual, progressive, or recurrent Grade II or III meningioma is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Meningioma

Drugs mentioned

• NEO100

Snippet

Sponsor: Neonc Technologies, Inc. | Conditions: Residual, Progressive or Recurrent Grade II or III Meningioma | Phase 2 | Status: RECRUITING